Enfermedades en Onco Wiki
OpenOnco coverage across 103 oncology diagnoses: biomarkers, drugs, indications/regimens/RedFlags, algorithm and questionnaire presence, fill and optional recorded content-review evidence.
Definiciones métricas
- #Bio — biomarcadores distintos referenciados por las indicaciones de esta enfermedad + regímenes
- #Droga — fármacos distintos en los regímenes de esta enfermedad
- #Ind / #Reg / #RF — Indicaciones / Régimen / RedFlags para esta enfermedad
- 1L / 2L — Algorithm presence for first-line / second-line+
- Búsqueda — ✓ de autor manual / STUB autogenerado / — ausente
- Llenar % — composite over 8 entity types: ≥1 indication, ≥1 regimen, ≥1 biomarker, ≥1 drug, ≥1 redflag, 1L algo, questionnaire, workup
- Ver % — % of this disease's indications with reviewer_signoffs ≥ 2 (CHARTER §6.1)
Proyecto individual. Una persona responsable publica las actualizaciones con comprobaciones automáticas y trazabilidad de las fuentes. La revisión clínica externa es opcional y se registra por separado.
Total de enfermedades
103
Lleno de la Avg
69.8%
Con algoritmo de 1L
87/103
Con algoritmo 2L+
55/103
103
No hay enfermedades que coincidan con tu búsqueda.
Abarcación de las enfermedades
Hematología linfoide (28)
| Enfermedad | ICD-10 | Biología | Fármaco | Ind | Reglamentación | RF | 1L | 2L | Búsqueda | Llenar % | Ver % |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ATLL Leucemia/linfoma de células T del adulto | C91.5 | 1 | 9 | 5 | 3 | 8 | ✓ | ✓ | — | 88% | 0% |
| ALCL Linfoma anaplásico de células grandes, sistémico | C84.6 | 2 | 6 | 5 | 5 | 5 | ✓ | ✓ | — | 88% | 0% |
| AITL Linfoma angioinmunoblástico de células T | C84.4 | 2 | 9 | 5 | 5 | 8 | ✓ | ✓ | — | 88% | 0% |
| B-ALL Leucemia linfoblástica B/Linfoma | C91.0 | 1 | 14 | 8 | 5 | 9 | ✓ | ✓ | — | 88% | 0% |
| BURKITT Linfoma de Burkitt | C83.7 | 3 | 15 | 10 | 6 | 10 | ✓ | ✓ | — | 88% | 0% |
| CLL Leucemia linfocítica crónica / Linfoma linfocito pequeño | C91.1 | 5 | 7 | 8 | 6 | 13 | ✓ | ✓ | ✓ | 88% | 0% |
| CHL Linfoma clásico de Hodgkin | C81.9 | 3 | 7 | 7 | 5 | 6 | ✓ | ✓ | — | 88% | 0% |
| DLBCL-NOS Linfoma difuso de células B grandes, sin otra especificación | C83.3 | 8 | 15 | 26 | 10 | 23 | ✓ | ✓ | — | 88% | 0% |
| NK-T-NASAL Linfoma extranodal NK/T-Cell, tipo nasal | C86.0 | 1 | 8 | 3 | 3 | 5 | ✓ | ✓ | — | 88% | 0% |
| FL Linfoma folicular | C82.0 | 3 | 12 | 9 | 8 | 9 | ✓ | ✓ | — | 88% | 0% |
| HCV-MZL Linfoma de la zona marginal asociado al VHC | C88.4 | 1 | 3 | 7 | 3 | 7 | ✓ | ✓ | ✓ | 88% | 0% |
| HGBL-DH Linfoma de células B de alto grado, double-hit / triple-hit | C83.3 | 5 | 8 | 3 | 3 | 7 | ✓ | ✓ | — | 88% | 0% |
| MCL Linfoma celular del manto | C83.1 | 5 | 12 | 7 | 6 | 9 | ✓ | ✓ | — | 88% | 0% |
| MM Mieloma múltiple | C90.0 | 2 | 13 | 16 | 13 | 14 | ✓ | ✓ | ✓ | 88% | 0% |
| MF-SEZARY Micosis Fungoides / Síndrome de Sézary | C84.0 | 1 | 3 | 5 | 4 | 5 | ✓ | ✓ | — | 88% | 0% |
| NODAL-MZL Linfoma de la zona marginal nodal | C83.0 | 3 | 3 | 4 | 3 | 5 | ✓ | ✓ | — | 88% | 0% |
| NLPBL Linfoma de células B predominante en los linfocitos nodulares | C81.0 | 1 | 5 | 3 | 2 | 6 | ✓ | ✓ | — | 88% | 0% |
| PTLD Trastorno linfoproliferativo posterior al trasplante | D47.Z1 | 3 | 5 | 3 | 3 | 6 | ✓ | ✓ | — | 88% | 0% |
| PCNSL Linfoma primario del SNC | C85.7 | 1 | 6 | 3 | 3 | 6 | ✓ | ✓ | — | 88% | 0% |
| PMBCL Linfoma B-Cell primario de mediastino grande | C85.2 | 1 | 8 | 3 | 3 | 8 | ✓ | ✓ | — | 88% | 0% |
| SPLENIC-MZL Linfoma de la zona marginal esplénica | C83.0 | 3 | 3 | 3 | 3 | 5 | ✓ | ✓ | — | 88% | 0% |
| T-PLL Leucemia prolifocítica T-Cell | C91.6 | 1 | 2 | 2 | 2 | 5 | ✓ | ✓ | — | 88% | 0% |
| WM Waldenström Macroglobulinemia / Linfoma linfoplasmacético | C88.0 | 2 | 6 | 5 | 5 | 7 | ✓ | ✓ | — | 88% | 0% |
| EATL Linfoma de células T asociada a la enteropatía | C86.2 | 0 | 7 | 4 | 2 | 6 | ✓ | — | — | 75% | 0% |
| HCL Leucemia de células peludas | C91.4 | 0 | 2 | 3 | 2 | 5 | ✓ | ✓ | — | 75% | 0% |
| HSTCL Linfoma hepatoesplénico de células T | C84.7 | 0 | 7 | 2 | 2 | 6 | ✓ | — | — | 75% | 0% |
| PTCL-NOS Linfoma periférico de células T, NOS | C84.4 | 0 | 8 | 4 | 4 | 5 | ✓ | ✓ | — | 75% | 0% |
| T-ALL Leucemia/linfoma T-lipoblástico | C91.0 | 0 | 9 | 2 | 2 | 9 | ✓ | ✓ | — | 75% | 0% |
| - la ag | 85.7% | 0.0% | |||||||||
Hematología mieloide (9)
| Enfermedad | ICD-10 | Biología | Fármaco | Ind | Reglamentación | RF | 1L | 2L | Búsqueda | Llenar % | Ver % |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AML Leucemia mieloide aguda | C92.0 | 4 | 13 | 39 | 10 | 37 | ✓ | ✓ | — | 88% | 0% |
| MASTOCYTOSIS Mastocitosis sistémica avanzada | C96.2, D47.09 | 1 | 2 | 2 | 2 | 6 | ✓ | — | — | 88% | 0% |
| PV Policitemia Vera | D45 | 1 | 5 | 6 | 4 | 6 | ✓ | ✓ | — | 88% | 0% |
| APL Leucemia promielocítica aguda | C92.4 | 0 | 4 | 4 | 4 | 9 | ✓ | ✓ | — | 75% | 0% |
| CML Leucemia mieloide crónica | C92.1 | 0 | 7 | 5 | 5 | 9 | ✓ | ✓ | — | 75% | 0% |
| ET Trombocitemia esencial | D47.3 | 0 | 3 | 3 | 2 | 7 | ✓ | ✓ | — | 75% | 0% |
| MDS-HR Síndromes mielodisplásicos: mayor riesgo | D46.2 | 0 | 2 | 7 | 3 | 15 | ✓ | ✓ | — | 75% | 0% |
| MDS-LR Síndromes mielodisplásicos: menor riesgo | D46.9 | 0 | 4 | 4 | 4 | 9 | ✓ | ✓ | — | 75% | 0% |
| PMF Mielofibrosis primaria | D47.4 | 0 | 3 | 5 | 4 | 7 | ✓ | ✓ | — | 75% | 0% |
| - la ag | 79.3% | 0.0% | |||||||||
Tumor sólido (66)
| Enfermedad | ICD-10 | Biología | Fármaco | Ind | Reglamentación | RF | 1L | 2L | Búsqueda | Llenar % | Ver % |
|---|---|---|---|---|---|---|---|---|---|---|---|
| THYROID-ANAPLASTIC Carcinoma anaplásico de tiroides | C73 | 1 | 4 | 2 | 2 | 7 | ✓ | — | — | 88% | 0% |
| BCC Carcinoma de células basales | C44 | 2 | 2 | 4 | 2 | 8 | ✓ | — | — | 88% | 0% |
| CERVICAL Carcinoma cervical | C53 | 2 | 7 | 9 | 4 | 17 | ✓ | — | — | 88% | 0% |
| CHOLANGIOCARCINOMA - El colangiocarcinoma | C22.1, C24.0 | 3 | 9 | 12 | 8 | 10 | ✓ | ✓ | — | 88% | 0% |
| CRC Carcinoma colorrectal | C18-C20 | 5 | 16 | 75 | 15 | 43 | ✓ | ✓ | — | 88% | 0% |
| MELANOMA Melanoma cutáneo | C43 | 2 | 12 | 15 | 8 | 19 | ✓ | ✓ | — | 88% | 0% |
| ENDOMETRIAL Carcinoma endometrial | C54 | 2 | 5 | 9 | 4 | 23 | ✓ | ✓ | — | 88% | 0% |
| ESOPHAGEAL Carcinoma esofágico | C15 | 3 | 13 | 19 | 10 | 15 | ✓ | ✓ | — | 88% | 0% |
| GI-NET Tumor neuroendocrino GI (carcinoide) | C17.9 | 1 | 1 | 1 | 1 | 6 | ✓ | — | — | 88% | 0% |
| GASTRIC Adenocarcinoma de unión gastrica y gastroesofágica | C16 | 5 | 18 | 19 | 9 | 25 | ✓ | ✓ | — | 88% | 0% |
| GIST Tumor del estroma gastrointestinal | C49 | 2 | 4 | 4 | 4 | 6 | ✓ | ✓ | — | 88% | 0% |
| GBM - El gluoblastoma | C71 | 2 | 2 | 6 | 4 | 8 | ✓ | ✓ | — | 88% | 0% |
| HNSCC Carcinoma de células escamosas de la cabeza y el cuello | C00-C14, C30-C32 | 1 | 6 | 9 | 5 | 9 | ✓ | ✓ | — | 88% | 0% |
| HCC Carcinoma hepatocelular | C22.0 | 4 | 10 | 32 | 8 | 23 | ✓ | ✓ | — | 88% | 0% |
| IFS Fibrosarcoma infantil | C49 | 1 | 1 | 1 | 1 | 5 | ✓ | — | — | 88% | 0% |
| IMT Tumor miofibroblástico inflamatorio | D48.1 | 1 | 1 | 1 | 1 | 5 | ✓ | — | — | 88% | 0% |
| BREAST Cáncer de mama invasivo | C50 | 11 | 26 | 84 | 19 | 65 | ✓ | ✓ | — | 88% | 0% |
| GLIOMA-LOW-GRADE Glioma de bajo grado | C71 | 1 | 3 | 9 | 1 | 11 | ✓ | — | — | 88% | 0% |
| LAM Linfangioleiomiomatosis | J84.81 | 1 | 1 | 1 | 1 | 1 | ✓ | — | — | 88% | 0% |
| MTC Carcinoma tiroideo medular | C73 | 1 | 2 | 6 | 2 | 8 | ✓ | — | — | 88% | 0% |
| NSCLC Cáncer de pulmón de células no pequeñas | C34 | 19 | 32 | 77 | 30 | 44 | ✓ | ✓ | — | 88% | 0% |
| OVARIAN Carcinoma de ovario | C56 | 4 | 11 | 25 | 11 | 34 | ✓ | ✓ | — | 88% | 0% |
| PDAC Adenocarcinoma ductal de páncreas | C25 | 1 | 9 | 18 | 5 | 36 | ✓ | ✓ | — | 88% | 0% |
| PNET Tumor neuroendocrino pancreático | C25.4 | 1 | 1 | 7 | 1 | 5 | ✓ | — | — | 88% | 0% |
| PROSTATE Adenocarcinoma de próstata | C61 | 4 | 10 | 9 | 8 | 27 | ✓ | ✓ | — | 88% | 0% |
| RCC Carcinoma de células renales | C64 | 1 | 7 | 27 | 7 | 23 | ✓ | ✓ | — | 88% | 0% |
| UROTHELIAL Carcinoma de urotelio | C67 | 1 | 6 | 16 | 6 | 20 | ✓ | ✓ | — | 88% | 0% |
| GRANULOSA-CELL Tumor de células granulosas adultas | C56 | 1 | 2 | 1 | 1 | 0 | ✓ | — | — | 75% | 0% |
| ANAL-SCC Carcinoma de células escamosas anales (CSC anal) | C21.0 | 0 | 5 | 3 | 3 | 2 | ✓ | — | — | 75% | 0% |
| CHONDROSARCOMA Condrosarcoma | C40, C41 | 0 | 1 | 1 | 1 | 5 | ✓ | — | — | 75% | 0% |
| EPITHELIOID-SARCOMA Sarcoma epitelioide | C49 | 1 | 1 | 1 | 1 | 0 | ✓ | — | — | 75% | 0% |
| KAPOSI Sarcoma de Kaposi | C46 | 1 | 4 | 11 | 4 | 4 | ✓ | — | — | 75% | 0% |
| LARYNGEAL Carcinoma de células escamosas laríngeas | C32 | 1 | 5 | 7 | 4 | 1 | ✓ | — | — | 75% | 0% |
| MESOTHELIOMA Mesotelioma maligno | C45.0 | 0 | 4 | 5 | 3 | 5 | ✓ | ✓ | — | 75% | 0% |
| MPNST Tumor maligno de la vaina del nervio periférico | C47 | 0 | 2 | 1 | 1 | 6 | ✓ | — | — | 75% | 0% |
| THYROID-PAPILLARY Carcinoma de tiroides papilar | C73 | 0 | 1 | 3 | 1 | 10 | ✓ | — | — | 75% | 0% |
| PARATHYROID-CARCINOMA Carcinoma paratiroideo | C75.0 | 2 | 2 | 3 | 2 | 1 | ✓ | — | — | 75% | 0% |
| PENILE-SCC Carcinoma de células escamosas del pene | C60 | 1 | 5 | 5 | 3 | 1 | ✓ | — | — | 75% | 0% |
| PITUITARY-ADENOMA Adenoma de pituitaria | D35.2 | 1 | 3 | 4 | 3 | 1 | ✓ | — | — | 75% | 0% |
| SALIVARY Carcinoma de la glándula salivaria | C07, C08 | 0 | 2 | 1 | 1 | 6 | ✓ | — | — | 75% | 0% |
| SCLC Cáncer de pulmón de células pequeñas | C34 | 0 | 7 | 7 | 7 | 16 | ✓ | ✓ | — | 75% | 0% |
| SOFT-TISSUE-SARCOMA Sarcoma de tejido blando | C49.9 | 0 | 6 | 10 | 4 | 8 | ✓ | ✓ | — | 75% | 0% |
| TGCT Tumor de células gigantes Tenosinovial | M12.2 | 1 | 1 | 1 | 1 | 0 | ✓ | — | — | 75% | 0% |
| TESTICULAR-GCT Tumor de células germinativas testiculares | C62.9 | 2 | 5 | 4 | 3 | 0 | ✓ | ✓ | — | 75% | 0% |
| VULVAR-VAGINAL-SCC Carcinoma de células escamosas vaginales y vulvares | C51, C52 | 1 | 2 | 5 | 2 | 3 | ✓ | — | — | 75% | 0% |
| ADRENOCORTICAL-CARCINOMA Carcinoma adrenocortical | C74.0 | 0 | 4 | 2 | 2 | 2 | ✓ | — | — | 62% | 0% |
| NPC Carcinoma nasofaríngeo | C11 | 0 | 3 | 2 | 2 | 1 | ✓ | — | — | 62% | 0% |
| PHEOCHROMOCYTOMA El tratamiento con el medicamento se realizará de forma que se pueda obtener un tratamiento de la salud de los animales. | D35.0 | 0 | 4 | 14 | 4 | 9 | ✓ | — | — | 62% | 0% |
| JMML Leucemia mielomonocítica juvenil | C93.3 | 0 | 0 | 1 | 1 | 0 | ✓ | — | — | 50% | 0% |
| MENINGIOMA Meningioma | D32 | 0 | 0 | 1 | 0 | 1 | ✓ | — | — | 50% | 0% |
| OSTEOSARCOMA Los demás | C40, C41 | 0 | 0 | 2 | 0 | 4 | — | — | — | 25% | 0% |
| WILMS Tumor de Wilms | C64 | 0 | 0 | 2 | 0 | 2 | — | — | — | 25% | 0% |
| LEIOMYOSARCOMA El leiomiosarcoma | C49, C54.2 | 0 | 0 | 0 | 0 | 2 | — | — | — | 12% | 0% |
| ATRT Atípico teratoide/tumor rabdoide | C71.9 | 0 | 0 | 0 | 0 | 0 | — | — | — | 0% | 0% |
| CHOROID-PLEXUS-CARCINOMA Carcinoma de plexo de coróides | C71.5 | 0 | 0 | 0 | 0 | 0 | — | — | — | 0% | 0% |
| CYSTIC-NEPHROMA Nefroma cístico | D30.0 | 0 | 0 | 0 | 0 | 0 | — | — | — | 0% | 0% |
| HEPATOBLASTOMA Hepatoblastoma | C22.2 | 0 | 0 | 0 | 0 | 0 | — | — | — | 0% | 0% |
| MEDULLOBLASTOMA Meduloblastoma | C71.6 | 0 | 0 | 0 | 0 | 0 | — | — | — | 0% | 0% |
| NEUROBLASTOMA Neuroblastoma | C74.9 | 0 | 0 | 0 | 0 | 0 | — | — | — | 0% | 0% |
| PARAGANGLIOMA Paraganglioma | D44.7 | 0 | 0 | 0 | 0 | 0 | — | — | — | 0% | 0% |
| PINEOBLASTOMA Pineoblastoma | C75.3 | 0 | 0 | 0 | 0 | 0 | — | — | — | 0% | 0% |
| PITUITARY-BLASTOMA Blostoma de pituitaria | C75.1 | 0 | 0 | 0 | 0 | 0 | — | — | — | 0% | 0% |
| PLEUROPULMONARY-BLASTOMA Blostoma pleuropulmonar | C34 | 0 | 0 | 0 | 0 | 0 | — | — | — | 0% | 0% |
| RETINOBLASTOMA Retinoblastoma | C69.2 | 0 | 0 | 0 | 0 | 0 | — | — | — | 0% | 0% |
| RHABDOMYOSARCOMA El rabdomiosarcoma | C49.9 | 0 | 0 | 0 | 0 | 0 | — | — | — | 0% | 0% |
| SERTOLI-LEYDIG-OVARIAN Tumor de las células Sertoli-Leydig | C56 | 0 | 0 | 0 | 0 | 0 | — | — | — | 0% | 0% |
| - la ag | 61.7% | 0.0% | |||||||||